Public Event Detail
ADMA kept revenue flat while ASCENIV sales climbed 28% in Q1
Public historical observation from the Merrowstone archive. This page shows event-level context only. Accepted assertions, evidence lineage, and relationship intelligence remain part of the premium research layer.
Event summary
ADMA Biologics reported flat revenue for Q1 2026 at $114.5 million, with ASCENIV sales increasing by 28% year-over-year to $97.5 million, while BIVIGAM sales declined significantly. Despite market competitive dynamics and distributor inventory pressures causing near-term top-line challenges and prompting ADMA to withdraw its long-term guidance, the company showcased strong profitability with Adjusted Net Income up 22% and Adjusted EBITDA up 24%. ADMA expressed confidence in ASCENIV's continued growth, driven by strong demand fundamentals.